An analysis by Triton Market Research has concluded that the European CRISPR market will bloom in terms of revenue at a CAGR of 22.99% in the forthcoming years 2019-2028.
The countries evaluated in the Europe CRISPR market are:
• Italy
• The United Kingdom
• Germany
• Russia
• France
• Spain
• Rest of Europe
Gene-editing in humans is not legal in the United Kingdom. A molecular biologist, Kathy Niakan and his team have been granted permission to utilize CRISPR/Cas9 technology on human embryos only for the purpose of better learning human embryo development. Other than these research scientists, no one else is permitted to use this technique in the country. The committee of HFEA provided the license on the condition that the embryos used in the various experiments must be received from donors. Also, the research team must work on embryos donated by women, who have already undergone the process of IVF (in-vitro fertilization) and having surplus embryos.
The researchers want to study the consequence of different genes in the first week of embryonic development, while the embryo has only 1 to 250 cells approximately. The license also declares that these embryos must be destroyed within 14 days, and are not permitted to be implanted in a woman. Such genetic modification studies are likely to help the researchers in the development of infertility treatment. However, it cannot be considered as a basis of therapy. These developments in the field are likely to boost the CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) market in the country in the forthcoming period.
Established in 2005, Horizon Discovery Ltd is a UK-based genomics company. It provides products, including genome editing tools, short hairpin ribonucleic acid, reporter kits and support services. It also offers in-vitro and in-vivo assay development in different sectors, like cell growth, apoptosis, signal transduction and metastasis. The company offers its services to diagnostic companies, the pharmaceutical & biotechnological sector and academic research centers. Horizon Discovery has its headquarters in Cambridge, UK and is operating majorly in Latin America, Asia-Pacific, Europe and Africa.
Some of the key companies in the CRISPR market are Intellia Therapeutics Inc, Cellectis, Sigma-Aldrich (Merck KGaA), GenScript, New England Biolabs, GeneCopoeia Inc, Origene Technologies Inc, Addgene, Horizon Discovery Ltd, Applied StemCell, Thermo Fisher Scientific Inc, Editas Medicine, DiaCarta, Caribou Biosciences Inc, Sangamo Therapeutics, Transposagen Bio (Hera BioLabs), Genedata AG, Precision Biosciences, Lonza, Integrated DNA Technologies Inc and CRISPR Therapeutics.